Related Experiment Video
Updated: Apr 11, 2026
06:03
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
2.3K
The code of non-coding RNAs in lung fibrosis
Huachun Cui1, Na Xie, Victor J Thannickal
1Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, 901 19th St. So., BMR II 233, Birmingham, AL, 35294, USA.
Cellular and Molecular Life Sciences : CMLS
|June 1, 2015
Summary
Non-coding RNAs (ncRNAs) play a crucial role in the complex pathogenesis of pulmonary fibrosis. Understanding these molecules offers new therapeutic potential for treating this debilitating lung disease.
Area of Science:
- Pulmonary medicine
- Molecular biology
- Genetics
Background:
- Pulmonary fibrosis pathogenesis involves complex cellular and signaling pathway dysregulation.
- Genetic, epigenetic, and post-transcriptional mechanisms contribute to lung fibrosis.
- Current therapeutics for pulmonary fibrosis remain limited.
Purpose of the Study:
- To review recent findings on the role of non-coding RNAs (ncRNAs) in pulmonary fibrosis pathogenesis.
- To analyze the translational potential of ncRNAs as therapeutics for lung fibrosis.
- To discuss challenges and future directions in ncRNA research for lung fibrosis.
Main Methods:
- Literature review of recent studies on ncRNAs and pulmonary fibrosis.
- Analysis of ncRNA functions in lung fibrosis models and patient data.
- Evaluation of ncRNA-based therapeutic strategies.
Main Results:
- Non-coding RNAs (ncRNAs) are increasingly recognized for their critical roles in the pathological progression of lung fibrosis.
- Specific ncRNAs have been identified as key regulators of fibrotic processes.
- ncRNAs demonstrate significant potential for targeted therapeutic interventions.
Conclusions:
- ncRNAs represent a promising class of molecules for developing novel treatments for pulmonary fibrosis.
- Further research is needed to overcome challenges in studying and utilizing ncRNAs in clinical settings.
- Exploiting ncRNAs offers new opportunities for managing and potentially reversing lung fibrosis.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
10.2K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.2K
02:39lncRNA - Long Non-coding RNAs
3.9K
3.9K
01:13Formation of Muscle Fibers from Myoblasts
7.4K
De novo myogenesis, or the formation of muscle fibers, begins during the early embryonic stages. The skeletal muscle is formed from somites– blocks of embryonic cell layers. The somites are further divided into dermatomes, myotomes, sclerotomes, and syndetomes. Among these, the myotomes give rise to muscle fibers.
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription...
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription...
7.4K